Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC

(2021) Jessica M Konen et al.   CANCER RESEARCH

Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade

(2021) Stéphane Terry et al.   CLINICAL CANCER RESEARCH

AXL inhibition in macrophages stimulates host-versus-leukemia immunity and eradicates naive and treatment resistant leukemia

(2021) Irene Tirado-Gonzalez et al.   Cancer Discovery

An epigenetic switch regulates the ontogeny of AXL positive/EGFR-TKI resistant cells by modulating miR-335 expression

(2021) Polona Safaric Tepes et al.   eLife

Single-cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer

(2020) Josephine A Taverna et al.   CANCER RESEARCH

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

(2020) Adam J Schoenfeld et al.   CLINICAL CANCER RESEARCH

ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer

(2020) Naoko Okura et al.   CLINICAL CANCER RESEARCH

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP

(2020) Yi Zhou et al.   IMMUNITY

AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation

(2020) Yu-Mi Yang et al.   LUNG CANCER

Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non‐small cell lung cancer patients

(2020) Lu Liu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The actin modulator hMENA regulates GAS 6‐ AXL axis and pro‐tumor cancer/stromal cell cooperation

(2020) Roberta Melchionna et al.   EMBO REPORTS

Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer

(2020) Rong Wang et al.   Nature Communications

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors

(2020) Giuseppe Schepisi et al.   Frontiers in Oncology

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer

(2020) Tong-Hong Wang et al.   Cancers

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity

(2020) Jonathan Rios-Doria et al.   Frontiers in Oncology

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells

(2019) Hirokazu Taniguchi et al.   Nature Communications

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas

(2019) Yoko Tsukita et al.   Molecular Cancer

Gilteritinib: First Global Approval

(2019) Sohita Dhillon   DRUGS

Pan-TAM tyrosine kinase inhibitor BMS-777607 enhances anti-PD-1 mAb efficacy in a murine model of triple-negative breast cancer

(2019) Canan Kasikara et al.   CANCER RESEARCH

Immuno-Oncological Efficacy of RXDX-106, a Novel Small Molecule Inhibitor of the TAM (TYRO3, AXL, MER) Family of Kinases

(2019) Yumi Yokoyama et al.   CANCER RESEARCH

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment

(2019) Kayla V. Myers et al.   Molecular Cancer

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

(2019) Donghwa Kim et al.   Cell Death & Disease

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

(2019) Qiming Wang et al.   Journal of Hematology & Oncology

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer

(2019) Miriam Molina-Arcas et al.   Science Translational Medicine

DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model

(2019) Takeshi Jimbo et al.   Oncotarget

AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity

(2019) Stéphane Terry et al.   Cancer Immunology Research

Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500

(2019) Laura Bonifacio et al.   CTS-Clinical and Translational Science

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer

(2019) Feng Wang et al.   Translational Cancer Research

Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients

(2018) Zhe Yang et al.   CLINICAL CANCER RESEARCH

Axl and MerTK receptor tyrosine kinases maintain human macrophage efferocytic capacity in the presence of viral triggers

(2018) Aleksander M Grabiec et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

(2018) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Receptor Tyrosine Kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors

(2018) Alexa B. Schrock et al.   Journal of Thoracic Oncology

The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis

(2018) B. R. Branchford et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

(2018) Julia Boshuizen et al.   NATURE MEDICINE

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial–mesenchymal transition is critical in conquering ALK-positive lung cancer

(2018) Shinji Nakamichi et al.   Oncotarget

MerTK mediates STAT3–KRAS/SRC-signaling axis for glioma stem cell maintenance

(2018) Hyojin Eom et al.   Artificial Cells Nanomedicine and Biotechnology

The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

(2018) Luiz E. B. Savio et al.   Frontiers in Pharmacology

Macrophage-Derived Protein S Facilitates Apoptotic Polymorphonuclear Cell Clearance by Resolution Phase Macrophages and Supports Their Reprogramming

(2018) Delphine Lumbroso et al.   Frontiers in Immunology

Abstract 827: Anti-tumor efficacy of BA3011, a novel Conditionally Active Biologic (CAB) anti-AXL-ADC

(2018) Leslie L. Sharp et al.   CANCER RESEARCH

A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.

(2018) Jordi Rodon Ahnert et al.   JOURNAL OF CLINICAL ONCOLOGY

MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents

(2018) Nellie K McDaniel et al.   MOLECULAR CANCER THERAPEUTICS

Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

(2018) Zofia Piotrowska et al.   Cancer Discovery

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib

(2018) Geoffrey R. Oxnard et al.   JAMA Oncology

LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

(2018) V A Papadimitrakopoulou et al.   ANNALS OF ONCOLOGY

LBA50Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

(2018) S S Ramalingam et al.   ANNALS OF ONCOLOGY

Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR-Mutant Non–Small Cell Lung Cancer Cells

(2018) Kei Namba et al.   MOLECULAR CANCER RESEARCH

Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

(2018) Jana Fassunke et al.   Nature Communications

PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?

(2017) Tawee Tanvetyanon et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Drug Resistance Driven by Cancer Stem Cells and Their Niche

(2017) Marta Prieto-Vila et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis

(2017) Tong Chen et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib

(2017) A. Oztan et al.   LUNG CANCER

Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs

(2017) Choong-kun Lee et al.   LUNG CANCER

Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression

(2017) Canan Kasikara et al.   MOLECULAR CANCER RESEARCH

MerTK as a therapeutic target in glioblastoma

(2017) Jing Wu et al.   NEURO-ONCOLOGY

cGAS is essential for the antitumor effect of immune checkpoint blockade

(2017) Hua Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models

(2016) Deborah DeRyckere et al.   CLINICAL CANCER RESEARCH

Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy

(2016) Frank C. Cackowski et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies

(2016) Mihalis S. Kariolis et al.   JOURNAL OF CLINICAL INVESTIGATION

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer

(2016) Peter Goldstraw et al.   Journal of Thoracic Oncology

AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers

(2016) Kavitha Balaji et al.   MOLECULAR CANCER RESEARCH

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erratum: Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia

(2016) A B Lee-Sherick et al.   ONCOGENE

Expression level of CRKL and AXL combined with exon 19 deletion in EGFR and ALK status confer differential prognosis of lung adenocarcinoma subtypes

(2016) Yi-Ran Cai et al.   Oncology Letters

Reprogramming the immunological microenvironment through radiation and targeting Axl

(2016) Todd A. Aguilera et al.   Nature Communications

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

(2016) J. F. Gainor et al.   Cancer Discovery

Mertk on tumor macrophages is a therapeutic target to prevent tumor recurrence following radiation therapy

(2016) Marka R. Crittenden et al.   Oncotarget

Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow

(2016) Younghun Jung et al.   Oncotarget

Liver X receptor and STAT1 cooperate downstream of Gas6/Mer to induce anti-inflammatory arginase 2 expression in macrophages

(2016) Si-Yoon Kim et al.   Scientific Reports

Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling

(2016) Cun Wang et al.   Theranostics

Targeting the TAM Receptors in Leukemia

(2016) Madeline Huey et al.   Cancers

The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy

(2016) Magdalena Paolino et al.   Cancers

Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

(2016) Katsuaki Sato et al.   PLoS One

Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma

(2015) H Yu et al.   BRITISH JOURNAL OF CANCER

AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas

(2015) Moshe Elkabets et al.   CANCER CELL

Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas

(2015) Zhenzhou Wu et al.   HUMAN PATHOLOGY

Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells

(2015) KYUNG-CHAN KIM et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

MERTK as negative regulator of human T cell activation

(2015) Raquel Cabezo´n et al.   JOURNAL OF LEUKOCYTE BIOLOGY

The 2015 World Health Organization Classification of Lung Tumors

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart

(2015) William D. Travis et al.   Journal of Thoracic Oncology

Longitudinal analysis of 2293 NSCLC patients: A comprehensive study from the TYROL registry

(2015) Florian Kocher et al.   LUNG CANCER

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR -mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI

(2015) Samuel J. Klempner et al.   LUNG CANCER

Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status

(2015) C. T. Cummings et al.   MOLECULAR CANCER THERAPEUTICS

Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells

(2015) Devon A. Lawson et al.   NATURE

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

(2015) Lecia V. Sequist et al.   NEW ENGLAND JOURNAL OF MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT

(2015) D N Debruyne et al.   ONCOGENE

Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer

(2015) XIAO-HAN QU et al.   Oncology Letters

Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells

(2015) Nitu Bansal et al.   Oncotarget

Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer

(2015) Song Yi Bae et al.   Oncotarget

Mer receptor tyrosine kinase is frequently overexpressed in human non-small cell lung cancer, confirming resistance to erlotinib

(2015) Shengzhi Xie et al.   Oncotarget

Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies

(2015) Katarzyna Wnuk-Lipinska et al.   CANCER RESEARCH

Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer

(2015) Christopher T. Cummings et al.   Oncotarget

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

(2015) Koichi Azuma et al.   Oncotarget

Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells

(2014) Brian Ruffell et al.   CANCER CELL

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors

(2014) Monica Mita et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs

(2014) C. Wilson et al.   CANCER RESEARCH

AXL Mediates Resistance to Cetuximab Therapy

(2014) T. M. Brand et al.   CANCER RESEARCH

Receptor Tyrosine Kinases, TYRO3, AXL, and MER, Demonstrate Distinct Patterns and Complex Regulation of Ligand-induced Activation

(2014) Wen-I Tsou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

(2014) Weihe Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer

(2014) Lanxi Song et al.   Journal of Thoracic Oncology

Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors

(2014) C. Feneyrolles et al.   MOLECULAR CANCER THERAPEUTICS

Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy

(2014) Carla L Esposito et al.   MOLECULAR THERAPY

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

(2014) Magdalena Paolino et al.   NATURE

An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis

(2014) Mihalis S Kariolis et al.   Nature Chemical Biology

Diversification of TAM receptor tyrosine kinase function

(2014) Anna Zagórska et al.   NATURE IMMUNOLOGY

Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR

(2014) YOUNG-SOO HONG et al.   ONCOLOGY REPORTS

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET

(2014) Erinn B. Rankin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer

(2014) E. C. de Bruin et al.   Cancer Discovery

Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities

(2014) Erin D Lew et al.   eLife

Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo

(2013) Nadine Jetten et al.   ANGIOGENESIS

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target

(2013) I.-K. Park et al.   BLOOD

TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase

(2013) X. Wang et al.   CANCER RESEARCH

MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation

(2013) J. K. Rho et al.   CANCER RESEARCH

Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma

(2013) Hsin-Jung Lee et al.   CARCINOGENESIS

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Novel therapeutic targets in non-small cell lung cancer

(2013) Muhammad Alamgeer et al.   CURRENT OPINION IN PHARMACOLOGY

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis

(2013) Rebecca S. Cook et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

(2013) Dong Hoon Shin et al.   JNCI-Journal of the National Cancer Institute

Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation

(2013) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

(2013) Keith M. Giles et al.   MOLECULAR CANCER THERAPEUTICS

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab

(2013) M. F. Burbridge et al.   MOLECULAR CANCER THERAPEUTICS

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy

(2013) W Leconet et al.   ONCOGENE

The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma

(2013) M A Cichoń et al.   ONCOGENE

Biology of the TAM Receptors

(2013) G. Lemke   Cold Spring Harbor Perspectives in Biology

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

(2013) A. O. Walter et al.   Cancer Discovery

Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients

(2012) Masashi Ishikawa et al.   ANNALS OF SURGICAL ONCOLOGY

Abstract 4736: Amplification of ERK2 mediates resistance to the novel irreversible EGFR inhibitor WZ4002

(2012) Dalia Ercan et al.   CANCER RESEARCH

An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

(2012) L. A. Byers et al.   CLINICAL CANCER RESEARCH

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

(2012) S. Betty Yan et al.   INVESTIGATIONAL NEW DRUGS

Efficient Clearance of Early Apoptotic Cells by Human Macrophages Requires M2c Polarization and MerTK Induction

(2012) G. Zizzo et al.   JOURNAL OF IMMUNOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation

(2012) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Axl With an High-affinity Inhibitory Aptamer

(2012) Laura Cerchia et al.   MOLECULAR THERAPY

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages

(2012) Emmanuel L Gautier et al.   NATURE IMMUNOLOGY

Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer

(2012) R M A Linger et al.   ONCOGENE

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cyclic GMP-AMP Is an Endogenous Second Messenger in Innate Immune Signaling by Cytosolic DNA

(2012) J. Wu et al.   SCIENCE

Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway

(2012) L. Sun et al.   SCIENCE

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

Galectin-3 is a new MerTK-specific eat-me signal

(2011) Nora B. Caberoy et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases

(2011) Silvia Novello et al.   Journal of Thoracic Oncology

Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib

(2011) Kenichi Suda et al.   Journal of Thoracic Oncology

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology

(2011) A E J Rogers et al.   ONCOGENE

Differentiation and Glucocorticoid Regulated Apopto-Phagocytic Gene Expression Patterns in Human Macrophages. Role of Mertk in Enhanced Phagocytosis

(2011) Gábor Zahuczky et al.   PLoS One

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy

(2010) A. K. Ghosh et al.   BLOOD

Differential Mechanisms of Acquired Resistance to Insulin-like Growth Factor-I Receptor Antibody Therapy or to a Small-Molecule Inhibitor, BMS-754807, in a Human Rhabdomyosarcoma Model

(2010) F. Huang et al.   CANCER RESEARCH

AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer

(2010) E. B. Rankin et al.   CANCER RESEARCH

Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis

(2010) Nora B Caberoy et al.   EMBO JOURNAL

Comprehensive Mapping of the Human Kinome to Epidermal Growth Factor Receptor Signaling

(2010) Kakajan Komurov et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Impaired Apoptotic Cell Clearance in the Germinal Center by Mer-Deficient Tingible Body Macrophages Leads to Enhanced Antibody-Forming Cell and Germinal Center Responses

(2010) Z. S. M. Rahman et al.   JOURNAL OF IMMUNOLOGY

TNF-α, IL-6, and IL-1 expression is inhibited by GAS6 in monocytes/macrophages

(2010) Federica Alciato et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data

(2010)   LANCET

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies

(2010) X Ye et al.   ONCOGENE

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer

(2010) K Vuoriluoto et al.   ONCOGENE

TGF-  IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

(2010) Z. Yao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

(2009) F. Qian et al.   CANCER RESEARCH

Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen

(2009) E. Lierman et al.   HAEMATOLOGICA

Survival and Migration of Human Dendritic Cells Are Regulated by an IFN- -Inducible Axl/Gas6 Pathway

(2009) S. Scutera et al.   JOURNAL OF IMMUNOLOGY

Discovery ofN-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily

(2009) Gretchen M. Schroeder et al.   JOURNAL OF MEDICINAL CHEMISTRY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis

(2009) Y Li et al.   ONCOGENE

Clinicopathologic and Molecular Features of Epidermal Growth Factor Receptor T790M Mutation and c-MET Amplification in Tyrosine Kinase Inhibitor-resistant Chinese Non-small Cell Lung Cancer

(2009) Hua-Jun Chen et al.   PATHOLOGY & ONCOLOGY RESEARCH

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression

(2008) Y.-X. Zhang et al.   CANCER RESEARCH

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations

(2008) S. Yano et al.   CANCER RESEARCH

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

(2008) J. Bean et al.   CLINICAL CANCER RESEARCH

METgene amplification orEGFRmutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

(2008) Takafumi Kubo et al.   INTERNATIONAL JOURNAL OF CANCER

Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins

(2008) Marta Guix et al.   JOURNAL OF CLINICAL INVESTIGATION

Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY

MerTK is required for apoptotic cell–induced T cell tolerance

(2008) Mark A. Wallet et al.   JOURNAL OF EXPERIMENTAL MEDICINE

In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3 kinase; in vitro mutagenesis defines the requisite binding sites for downstream Akt activation

(2008) Jason G. Weinger et al.   JOURNAL OF NEUROCHEMISTRY

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE

Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1

(2008) K-Y Tai et al.   ONCOGENE

Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase

(2008) Patrizia Pellegatti et al.   PLoS One

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA